Recent trials comparing triple therapy with LAMA/LABA in COPD reveal a peculiar pattern in the timing of exacerbations, with the benefit of triple therapy exclusively in the first month, suggesting a precision medicine opportunity in COPD treatmenthttp://ow.ly/WBFb30m9ZeM
No takes yet. Share an insight, caveat, or question.
Suissa et al. (2018) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: